Enhanced NADH/NADPH oxidase activity and increased production of ROS could lead to myocardial hypertrophy, and also the application of antioxidants such as GSH-Px could significantly reduce myocardial hypertrophy (Amin et al., 2001; MacCarthy et al., 2001; Shiomi et al., 2004). The gene discussed is FMO5; the disease is cardiac hypertrophy.